Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Melanoma Institute Australia
Condition: Cutaneous Squamous Cell Carcinoma
NCT06288191
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.